Clinical Trials Logo

Fever clinical trials

View clinical trials related to Fever.

Filter by:

NCT ID: NCT05926063 Recruiting - Clinical trials for Neutropenia, Febrile

Stopping Antibiotics After 3 Days for the Treatment of High-risk FEbrile Neutropenia

SAFE
Start date: February 26, 2024
Phase: Phase 4
Study type: Interventional

The goal of this clinical trial is to compare a short course of antibiotics in patients in whom no bacterial infection is found with the current "golden standard": long-term antibiotic treatment in adult hematology patients who develop neutropenic fever. The main question it aims to answer is: whether the short-term treatment is equally safe for patients, hence the name 'SAFE study'. Participants will be randomly assigned (randomized) to one of two treatment options once they develop neutropenic fever: short-term or long-term antibiotic treatment. An additional blood sample, urine sample and stool sample will be collected. Researchers will compare the short-term and the long-term antibiotic treatment groups to see if the short treatment is equally safe as the long-term treatment group.

NCT ID: NCT05901454 Recruiting - Yellow Fever Clinical Trials

Yellow Fever Human Infection Model With YF-17D

YF-INFECT
Start date: February 17, 2023
Phase: N/A
Study type: Interventional

No antiviral treatment exists for yellow fever, only supportive care, and therefore we rely on prevention through vaccination. Although this vaccine is very effective, stockpiles are insufficient in outbreak situations and some people have a contraindication to be vaccinated. For those who are unprotected and at risk of yellow fever infection, treatment could be life saving.

NCT ID: NCT05889390 Recruiting - Clinical trials for HER2-negative Breast Cancer

Neoadjuvant Concomitant Modulated Electro-hyperthermia in HER2-negative Breast Cancer

NeoHTerMa
Start date: February 20, 2023
Phase: Phase 2/Phase 3
Study type: Interventional

The aim of this study is to investigate whether the application of concomitant modulated electro-hyperthermia in a neoadjuvant chemotherapeutic setting is beneficial for patients with HER2-negative, stage II-III breast cancer.

NCT ID: NCT05868733 Recruiting - Lassa Fever Clinical Trials

A Lassa Fever Vaccine Trial in Adults and Children Residing in West Africa

Start date: March 6, 2024
Phase: Phase 2
Study type: Interventional

A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of rVSV∆G-LASV-GPC Vaccine in Adults and Children Residing in West Africa

NCT ID: NCT05860153 Not yet recruiting - Febrile Convulsion Clinical Trials

Intermittent Levetricetam in Treatment of Febrile Convulsions

Start date: June 1, 2023
Phase: N/A
Study type: Interventional

The American Academy of Pediatrics (AAP) in 2011 published a clinical practice guideline defining a febrile seizure as "a seizure accompanied by fever (temperature ≥ 100.4°F or 38°C by any method), without central nervous system infection, that occurs in infants and children 6 through 60 months of age." Febrile seizures are further classified as simple (generalized in onset, last less than 15 minutes, and do not occur more than once in 24 hours.) or complex (FS duration longer than 15 min, repeated convulsions within the same day, and focal seizure activity or focal findings during the postictal period.).

NCT ID: NCT05859490 Recruiting - Clinical trials for Immunization; Infection

Immunogenicity of Yellow Fever Vaccine 17D in Adults With Prior 17D Vaccination

Start date: August 1, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

The goal of this clinical trial is to assess the immune response to the yellow fever vaccine 17D in adults with prior 17D vaccination. The main questions this study aims to answer are: - how does prior vaccination affect antibody responses to re-vaccination? - how does prior vaccination affect the immune cell response to re-vaccination? Participants will: - have been previously vaccinated with 17D. - be re-vaccinated with 17D. - provide medical and travel histories. - provide a blood sample prior to vaccination - provide a blood sample approximately every other day for 14 days after vaccination. - provide a blood sample approximately 28 days after vaccination. - complete a daily diary of symptoms following vaccination for 14 days. - report any additional symptoms after 14 days.

NCT ID: NCT05816551 Active, not recruiting - Aging Clinical Trials

Aging and Gastrointestinal Barrier Function

Start date: July 1, 2023
Phase:
Study type: Observational

The purpose of this study is to assess the gastrointestinal responses of the elderly during hyperthermia.

NCT ID: NCT05814302 Completed - Fever Clinical Trials

Treatment Of Fever In The Emergency Department

Start date: June 1, 2021
Phase:
Study type: Observational

Fever is a frequent cause of admission to the Emergency Department (ED) around the world. While it can be caused by a wide range of conditions, the most effective treatment based on its etiology is still undetermined. This observational, prospective, single-center study enrolled adult patients who accessed the ED for fever, with the aim to define the most effective treatment for them.

NCT ID: NCT05787782 Completed - Fever Clinical Trials

Validation of the Masimo INVSENSOR00063 in Febrile and Afebrile Subejcts

Start date: February 23, 2023
Phase: N/A
Study type: Interventional

This is a prospective, non-randomized data collection study to evaluate the performance of the Masimo INVSENSOR00063 in obtaining temperature measurements.

NCT ID: NCT05786495 Not yet recruiting - Febrile Neutropenia Clinical Trials

Short Antibiotic Treatment in High Risk Febrile Neutropenia

Start date: May 1, 2023
Phase: N/A
Study type: Interventional

Infections are a common complication in patients with cancer. They are a significant cause of complications and death in this population. Patients with cancer and low neutrophil counts due to chemotherapy or disease often have a fever and receive antibiotic treatment. The optimal duration of this treatment is largely unknown. Late, there have been some data suggesting the safety of early discontinuation of antibiotics, though most centers still give more prolonged antibiotic therapies in this situation. The unnecessary prolonged antibiotic use may increase infections with multi-drug-resistant bacteria, which carry a high death rate. Also, an increase in infections caused by Clostridioides difficile and an increase in fungal infections can happen. However, some are concerned that stopping antibiotics while the neutrophil count is still low will result in life-threatening infections. Our study aims to test whether shorter antibiotic treatment in these situations is as safe as more prolonged treatment, resulting in better antibiotic prescription practices in this population.